Live
- Belagavi glows celebrating centenary of historic Congress session
- Tigress ‘Rani’ at Pilikula zoo delivers two cubs
- For 10 yrs, govts have not followed 60-day session rule
- Now cattle to be issued Aadhaar ID
- OnePlus 12 Price Slashes to Rs 52,999 Ahead of OnePlus 13 Launch
- Vijayawada: Christmas celebrated at PB Siddhartha
- Tremors due to adjustments in Gundlakamma fault: Scientists
- IG lauds police for crime control in district
- Revised biography of Naveen not based on facts: BJD
- Churches decked up to celebrate Christmas
Molnupiravir barred from India's Covid treatment
The ICMR's National Task Force for Covid-19 has decided against including antiviral drug Molnupiravir in the Clinical Management Protocol for Covid as of now, official sources said on Tuesday.
New Delhi: The ICMR's National Task Force for Covid-19 has decided against including antiviral drug Molnupiravir in the Clinical Management Protocol for Covid as of now, official sources said on Tuesday.
The experts of the task force cited safety concerns and argued that Molnupiravir was not of much benefit in Covid treatment to arrive at the decision in a meeting held on Monday.
According to the Health Ministry, Molnupiravir is an antiviral drug that inhibits SARS-CoV-2 replication by viral mutagenesis.
This anti-Covid pill got the Drug Regulator General of India's approval on December 28 for restricted use in emergencies. Mutagenesis is a process by which the genetic information of an organism is changed by the production of mutation.
"Members of the National Task Force for COVID-19 were not in favour of including the drug in the national treatment guidelines citing that it does not have much benefit in the treatment of coronavirus infection and that there were safety concerns," an official source told PTI.
Indian Council of Medical Research (ICMR) chief Dr Balram Bhargava had last week said that Molnupiravir has major safety concerns. He added that WHO and the UK have not included it for treatment.
"We have to remember that this drug has major safety concerns," he said, adding, it can cause defects in a developing fetus and can damage the muscles also. "Contraception will have to be done for three months for male and female if this drug is given because the child born could be problematic due to teratogenic influence," Dr Bhargava had said.
The UK Medicines and Healthcare products Regulatory Agency had on December 4 granted approval for Molnupiravir under special conditions for treatment of mild to moderate COVID-19 in adults who have at least one risk factor for developing severe illness.
